A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma by 媛뺤긽�슧 et al.
A Metabolic Phenotype Based on Mitochondrial Ribosomal
Protein Expression as a Predictor of Lymph Node Metastasis
in Papillary Thyroid Carcinoma
Jandee Lee, MD, PhD, Mi-Youn Seol, MA, Seonhyang Jeong, BA, Cho Rok Lee, MD,
MD, Jong Ju Jeong, b Shin, MD,
MDCheol Ryong Ku, MD, PhD, Sang-Wook Kang,
Kee-Hyun Nam, MD, PhD, Eun Jig Lee,k J
cellular acidification rates (ECARs), and amounts of OxPhos complexes
were consistently observed in BCPAP, TPC1, HTH-7, and XTC.UC1
cell lines. In PTCs, metabolic phenotype according to OxPhos amount
burg effect, cancer ce
dominantly through
phenotype) rather tha
Editor: Peng Qi.
Received: October 2, 2014; revised: November 23, 2014; accepted:
November 26, 2014.
From the Department of Surgery (JL, M-YS, CRL, S-WK, JJJ, K-HN,
WYC); and the Department of Internal Medicine (SJ, CRK, DYS, EJL,
YSJ), Severance Hospital, Yonsei Cancer Center, Yonsei University
College of Medicine, Seoul, Korea.
Correspondence: Young Suk Jo, Department of Internal Medicine,
Severance Hospital, Yonsei Cancer Center, Yonsei University College
of Medicine, 120-752, Seoul, Korea (e-mail: joys@yuhs.ac).
This study was supported by the National Research Foundation of Korea
grant funded by the Korea government (MEST) (2012R1A
2A2A01014672).
The authors have no conflicts of interest to disclose.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike 4.0 License, which
allows others to remix, tweak, and build upon the work non-commercially,
as long as the author is credited and the new creations are licensed under
the identical terms.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000000380
Medicine  Volume 94, Number 2, January 2015MD, Dong Yeo
un Chung, MDand Young Su
Abstract:Metabolic reprogramming has been regarded as an essential
component of malignant transformation. However, the clinical signifi-
cance of metabolic heterogeneity remains poorly characterized.
The aim of this study was to characterize metabolic heterogeneity in
thyroid cancers via the analysis of the expression of mitochondrial
ribosomal proteins (MRPs) and genes involved in oxidative phosphoryl-
ation (OxPhos), and investigate potential prognostic correlations.
Gene set enrichment analysis (GSEA) verified by reverse transcrip-
tion polymerase chain reaction and gene network analysis was per-
formed using public repository data. Cross-sectional observational
study was conducted to classify papillary thyroid cancer (PTC) by
the expression of MRP L44 (MRPL44) messenger RNA (mRNA), and
to investigate the clinicopathological features.
GSEA clearly showed that the expression of OxPhos and MRP gene
sets was significantly lower in primary thyroid cancer than in matched
normal thyroid tissue. However, 8 of 49 primary thyroid tumors (16.3%)
in the public repository did not show a reduction in OxPhos mRNA
expression. Remarkably, strong positive correlations between MRPL44
expression and those of OxPhos and MRPs such as reduced nicotina-
mide adenine dinucleotide dehydrogenase (ubiquinone) 1 a subcom-
plex, 5; succinate dehydrogenase complex, subunit D; cytochrome c,
somatic; adenosine triphosphate synthase, Hþ transporting, mitochon-
drial Fo complex, subunit C1 (subunit 9); and MRP S5 (MRPS5)
(P< 0.0001) were clearly denoted, suggesting that MRPL44 is a
representative marker of OxPhos and MRP expressions. In laboratory
experiments, metabolic heterogeneity in oxygen consumption, extra-, PhD, Woong Yo , PhD,
o, MD, PhD
defined by expression of MRPL44 mRNA was significantly related to
lymph node metastasis (LNM) (P< 0.001). Furthermore, multivariate
analysis clearly indicated that expression of MRPL44 is associated with
an increased risk of lateral neck LNM (odds ratio 9.267, 95% confidence
interval 1.852–46.371, P¼ 0.007).
MRPL44 expression may be a representative marker of metabolic
phenotype according to OxPhos amount and a useful predictor of LNM.
(Medicine 94(2):e380)
Abbreviations: 18F-FDG PET = [18F]-fluorodeoxyglucose positron
emission tomography, ATP5G1 = ATP synthase, Hþ transporting,
mitochondrial Fo complex, subunit C1 (subunit 9), Ckmt = creatine
kinase, mitochondrial, CYCS = cytochrome c, somatic, ETCe =
lectron transport chain, ETE = extrathyroidal extension, GSEA =
gene set enrichment analysis, LNM = lymph node metastasis, MRP
= mitochondrial ribosomal protein, MRPL44 = MRP L44, MRPS5
= MRP S5, NDUFA5 = NADHdehydrogenase (ubiquinone) 1 a
subcomplex, 5, OxPhos = oxidative phosphorylation, PTC =
papillary thyroid cancer, SDHD = succinate dehydrogenase
complex, subunit D.
INTRODUCTION
P apillary thyroid cancer (PTC) is the most common endocrinemalignancy whose incidence is rapidly increasing world-
wide.1 However, the treatment strategy of PTC is controversial
because patients with PTC have widely different prognoses.2 On
one hand, an observational study suggested that awatch-and-wait
policy may be sufficient to manage patients with small PTCs.3,4
On the other hand, persistent or recurrent PTC occurs in around
10% to 15% of the cases.5 Moreover, as the survival rate of
persistent or recurrent PTC is around 50% to 70%, a significant
proportion of PTC cases are fatal.6
Many investigators have carried out laboratory and clinical
studies with the aim of finding new markers to predict the
presence of poor prognostic factors such as extrathyroidal
extension (ETE) or lymph node metastasis (LNM) to charac-
terize persistent or recurrent PTC at initial diagnosis. In this
regard, the v-Raf murine sarcoma viral oncogene homolog B
(BRAF)V600E mutation, galectin-3, and human mesothelial cell
1 are all considered potential candidates for the prediction of
prognosis.1,7–10 Nonetheless, the clinical applications of these
molecular markers are still limited.
Metabolic reprogramming is an essential component of
malignant transformation. Following the discovery of the War-lls were shown to produce energy pre-
higher glycolytic activity (glycolytic
n through oxidative phosphorylation
www.md-journal.com | 1
(OxPhos) using the electron transport chain (ETC).11–13 How-
ever, in addition to aerobic glycolysis (Warburg effect), gluta-
mine addiction, somatic isocitrate dehydrogenase mutations,
glycine/serine addiction, and the reverse Warburg effect
suggested the existence of diverse metabolic phenotypes in
cancer cells.14–18 In addition, cancer cells generating cellular
adenosine triphosphate (ATP) through OxPhos (oxidative phe-
notype) have been observed.19,20 Taken together, these studies
indicate substantial intertumor heterogeneity with respect to cell
metabolism, although the mechanism of action and clinical
implications of the different metabolic phenotypes are not well
characterized.
Herein, we carried out gene set enrichment analysis
(GSEA) using public repository data combined with reverse
transcription polymerase chain reaction (RT-PCR) verification
in a cohort of primary tumors to shed light on metabolic
heterogeneity in PTC. We also determined if expression of
OxPhos-related genes and mitochondrial ribosomal proteins
(MRPs) could be used to identify metabolic phenotypes. In
addition, gene network analysis and immunohistochemical
staining data of OxPhos-related proteins and MRPs available
at the Human Protein Atlas (HPA) were also analyzed. Based on
functional analysis using thyroid cancer cell lines, both cell
lines and primary tumors were classified as either having a
glycolytic phenotype or a combined (glycolytic and oxidative)
phenotype. Moreover, the metabolic phenotype according to
OxPhos amount could be inferred by measuring the expression
of MRP L44 (MRPL44) messenger RNA (mRNA). Interest-
ingly, expression of MRPL44 was associated with the presence
of LNM, which suggests that it may be a useful clinical marker
for predicting poor prognosis and planning the extent of surgery.
METHODS
Subjects and Clinical Data
This study enrolled 103 patients (20 males and 83 females)
undergoing thyroidectomy for classical PTC between January
2012 and December 2013 at Severance Hospital, Yonsei Cancer
Center, Seoul, Korea. The study size was calculated by Web-
based Sample Size/Power Calculations (http://www.stat.ubc.ca/
rollin/stats/ssize/). All samples were microscopically dis-
sected at the time of surgery after confirmation of diagnosis
using frozen sections. Samples were taken from the central
portion of the tumor and from contralateral normal tissue. On
histological examination, cellularity was >90%. Slides stained
with hematoxylin and eosin were reviewed independently by 2
pathologists and a histological diagnosis was made according to
the WHO classification. Patient information and clinicopatho-
logical parameters were analyzed. All protocols were approved
by the institutional review board of Severance Hospital.
RNA Isolation and RT-PCR
Total RNA was extracted using Trizol (Invitrogen, Carls-
bad, CA), and complementary DNA (cDNA) was prepared from
total RNA using M-MLV reverse transcriptase (Invitrogen) and
oligo-dT primers (Promega, Madison, WI). RT-PCR was per-
formed on cDNA using the Solg 2X PCR Smart mix Kit
(Solgent, Daejeon, South Korea). Genes were amplified using
the following primers: reduced nicotinamide adenine dinucleo-
tide (NADH) dehydrogenase (ubiquinone) 1 b subcomplex,
Lee et al3 (NDUFB3), 50-GGA CAT GAG CAT GGA CAT CA-30 and
50-GCA AAG CCA CCC ATG TAT CT-30; NADH dehydro-
genase (ubiquinone) 1 a subcomplex, 5 (NDUFA5), 50-GGT
2 | www.md-journal.comGTGCTGAAGAAGACCAC-30 and 50-GCAGGAGGCTCT
TCC ACTAA-30; succinate dehydrogenase complex, subunit D
(SDHD), 50-TGT TGC TTCGAACTCCAG TG-30 and 50-CCC
AGC AAA GGT TAA AGC TG-30; cytochrome c1 (CYC1), 50-
CCA AAA CCATAC CCC AAC AG-30 and 50-GTT TTC GAT
GGT CGT GCT CT-30; cytochrome c, somatic (CYCS), 50-CCA
AAA CCATAC CCC AAC AG-30 and 50-GTT TTC GAT GGT
CGT GCT CT-30; cytochrome c oxidase subunit VIa polypep-
tide 1 (COX6A1), 50-TTTGTCATCACTGGGAACCA-30 and
50-ATG AAC TCG GGT CTC TCG TG-30; cytochrome c
oxidase subunit VIIb (COX7B), 50-AAG CGC ACT AAA
TCG TCT CC-30 and 50-TTT GGG GTA ACT CTG CCA
AC-30; ATP synthase, Hþ transporting, mitochondrial Fo com-
plex, subunit C1 (subunit 9) (ATP5G1), 50-GGT GTG CTG
AAGAAGACCAC-30 and 50-GCAGGAGGC TCT TCCACT
AA-30; MRPL44, 50-GTT CAG AGA AGC CGA ACT GG-30
and 50-ACT GCT CCA CAG CCA AGT TT-30; MRP L45
(MRPL45), 50-CCC CAT ACC TCA AGG GTT CT-30 and
50-CCG GAT TGA CAC TTG TGATG-30; MRP S5 (MRPS5),
50-TTT GTC ATC ACT GGG AAC CA-30 and 50-CTG CAC
TGC TCCATT TTT CA-30; MRP S11 (MRPS11), 50-AGCATT
TAC CCT CCC ATT CC-30 and 50-TGG GGT GTT GTC TGT
GAT TG-30; MRP S28 (MRPS28), 50-CCC CTA CAG AAG
GGT TCT CC-30 and 50-TGG ATT CCC AAG AGA ACT GC-
30; MRP S31 (MRPS31), 50-CAG TCA GGT ACC GCA GTT
CA-30 and 50-AAG GGA GAG AAT CTG CCA CA-30; gly-
ceraldehyde-3-phosphate dehydrogenase, 50-TTG ATT TTG
GAG GGA TCT CG-30 and 50-GAG TCA ACG GAT TTG
GTC GT-30. RT-PCR experiments were repeated 3 times, and
each experiment was performed in triplicate.
Public Data and Statistical Analysis
Microarray data from the Gene Expression Omnibus of
NCBI (gene expression data available at www.ncbi.nlm.nih.-
gov/projects/geo; accession no. GSE6004 and GSE33630) were
subjected to GSEA. Analysis of public repository data was
performed using the HPA (http://www.proteinatlas.org/) and
GeneNetwork (a free scientific web resource, http://www.ge-
nenetwork.org/). Statistical analysis was carried out using SPSS
version 18.0 for Windows (SPSS Inc, Chicago, IL) or GraphPad
Prism (GraphPad Software, Inc, San Diego, CA). Average
means were compared with a Mann–Whitney U test. Data
are presented as meanSD. All P values are 2 sided.
Cell Culture, Oxygen Consumption Rate, and
ECAR
HELA, BCPAP, TPC1, HTH-7, and XTC.UC1 cells were
cultured in Dulbecco modified Eagle medium (DMEM, Life
Technologies, Carlsbad, CA) or Roswell Park Memorial Insti-
tute medium (Life Technologies) containing 4.5 g/L glucose,
10% fetal calf serum, 0.1mMNEAA, and 50mg/mL gentamicin
at 378C in a 5% CO2 atmosphere.
21 The mitochondrial oxygen
consumption rate (OCR) was measured using a Seahorse XF-96
extracellular flux analyzer (Seahorse Bioscience Inc, North
Billerica, MA).22,23 On the day before the experiment, the
sensor cartridge was placed in the calibration buffer supplied
by Seahorse Bioscience and incubated at 378C without CO2.
Cells were cultured on Seahorse XF-24 plates at a density of
20,000 cells per well, washed, and incubated with assay med-
ium (DMEM without bicarbonate) at 378C without CO for 1
Medicine  Volume 94, Number 2, January 20152
hour. All media and injection reagents were adjusted to pH 7.4
on the day of the assay. Three baseline measurements of the
OCR and ECAR were taken.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Isolation of Mitochondria and BN-PAGE
Isolation of mitochondria and blue native (BN) BN-PAGE
was performed as described previously using the NativePAGE
Novex Bis-Tris Gel system (Invitrogen).24 Briefly, cells were
homogenized in isolation buffer B (210mM Mannitol, 70mM
sucrose, 1mM EGTA, 5mM HEPES, pH 7.2) with a Teflon-
glass homogenizer. The homogenate was then centrifuged at
600g for 10 minutes at 48C, and the resulting supernatant was
recentrifuged at 17,000g for 10 minutes at 48C. The mito-
chondrial fractions, which were recovered in the pellet, were
washed with buffer B and resuspended in the same buffer.
Mitochondria were either used immediately or stored at
808C for later use. Isolated mitochondria (50mg) were solu-
bilized using NativePAGE sample buffer with 0.5% n-dodecyl-
b-D-maltoside or 1% digitonin (Invitrogen). The suspensions
were centrifuged at 20,000g for 10 minutes at 48C. The
resulting supernatants were loaded onto a NativePAGE Novex
3% to 12% Bis-Tris gel (Invitrogen). After the run was com-
plete, the gel was transferred to a PVDF membrane using the
iBlot Gel Transfer System (Invitrogen). The membrane was
fixed with 8% acetic acid. After overnight drying, the mem-
brane was destained with methanol. To detect the OxPhos
complex, the Mitoprofile Total OXPHOS Rodent WBAntibody
Medicine  Volume 94, Number 2, January 2015Cocktail, Abcam, Cambridge, MA, USA (Mitosciences/
Abcam) was used. After incubation in the primary antibody
dilution, the membrane was washed and visualized using the
A
Enrichment score 0.38458133
Nominal P value 0.039583333
FDR q value 0.2248908
B
Normal
Enrichment score 0.5061085
Nominal P value 0.0021881838
FDR q value 0.001
Normal
FIGURE 1. GSEA using public repository data (GSE336300). (A) G
mitochondrial ribosomal pathway gene set. ATC¼ anaplastic thy
OxPhos¼oxidative phosphorylation, PTC¼papillary thyroid cancer.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.WesternBreeze Chromogenic Western Blot Immunodetection
Kit (Invitrogen).
RESULTS
Metabolic Heterogeneity According to mRNA
Expression of OxPhos Proteins and MRPs in PTC
To confirm the heterogeneity of mRNA expression of
OxPhos and MRPs in PTC, we performed GSEA using public
repository data. In the analysis using GSE33630 (n¼ 105), both
the OxPhos gene set (P¼ 0.0395, false discovery rate (FDR) q
value¼ 0.225, Figure 1A) and the MRP gene set (P¼ 0.0022,
FDR q value¼ 0.001, Figure 1B) showed statistically significant
enrichment in normal thyroid tissues. In addition, in the analysis
using GSE6004 (n¼ 18), the OxPhos and MRP gene sets were
consistently enriched in normal thyroid tissues (P¼ 0.0388, FDR
q value< 0.05; P¼ 0.002, FDR q value< 0.01, respectively;
Supplementary Figure 1A and B, http://links.lww.com/MD/
A138). In agreement with the Warburg effect (aerobic glycoly-
sis), GSEA clearly indicated a reduction in OxPhos and MRP
gene sets, suggesting that cancer cells from both papillary and
anaplastic thyroid cancers (ATC) predominantly produce energy
via a high rate of glycolysis. However, through careful review of
MRPL44 as a Prognostic Marker in PTCthe raw data in GSEA (GSE33630), we found that 8 of 49 PTC
cases (16.3%) did not show a reduction in OxPhos mRNA
expression (Supplementary Figure 2, http://links.lww.com/
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MD/A138). In addition, the HPA program (used to explore the
entire human proteomeusing an antibody-based approach funded
by the nonprofit organization Knut and Alice Wallenberg
Foundation) indicated that expression of MRPL44 was not
decreased in all PTCs. As shown in Supplementary Figure 3A,
http://links.lww.com/MD/A138, normal thyroid follicular cells
showed moderate MRPL44 staining, whereas PTC cells showed
low (Supplementary Figure 3B, http://links.lww.com/MD/A138)
to moderate (Supplementary Figure 3C, http://links.lww.com/
MD/A138) staining, suggesting heterogeneous expression of
MRPs in PTCs. In addition, the staining intensity of NDUFA5
was also moderate to strong in PTC (Supplementary Figure 4,
http://links.lww.com/MD/A138). To further investigate the
observed intertumor heterogeneity of OxPhos protein and
MRP expression, we analyzed the correlation between mRNA
expression of OxPhos and MRP genes using the raw data from
GSE33630. Interestingly, expression of MRP mRNA showed a
statistically significant correlation with OxPhos mRNA expres-
sion (Figure 2A and B and Supplementary Figure 5, http://
links.lww.com/MD/A138). MRPL44 expression also presented
Lee et alstrong positive correlations with NDUFA5 (r¼ 0.1691,
P< 0.0001, Figure 2A), SDHD (r¼ 0.4703, P< 0.0001,
Figure 2B), CYCS (r¼ 0.2441, P< 0.0001, Supplementary
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4 | www.md-journal.comFigure 5A, http://links.lww.com/MD/A138), and ATP5G1
(r¼ 0.2586, P< 0.0001, Supplementary Figure 5B, http://
links.lww.com/MD/A138). The data set GSE16780 UCLA
Hybrid MDP Liver Affy HT M430A (Sep11) RMA, Supple-
mentary Figure 6A, http://links.lww.com/MD/A138) from Gen-
eNetwork consistently revealed the presence of a strong positive
correlation between the expression ofMrpl44 and the expression
of ATP synthase, Hþ transporting, mitochondrial Fo complex,
subunit C2 (subunit 9) (Atp5g2) (Figure 2C and Supplementary
Figure 6B, http://links.lww.com/MD/A138), mitochondrial
creatine kinase (Ckmt, Figure 2D and Supplementary Figure
6C, http://links.lww.com/MD/A138), and Mrps5 (Figure 2E
and Supplementary Figure 6D, http://links.lww.com/MD/
A138). Taken together, these data indicated significant intertu-
mor heterogeneity in OxPhos and MRP mRNA expression.
Accordingly,MRPs such asMRPL44may be useful as indicators
of the expression pattern of OxPhos and MRPs.
Metabolic Phenotype in Thyroid Cancer Cell
Lines
Medicine  Volume 94, Number 2, January 2015Considering the differential expression of OxPhos and
MRP genes, we postulated that a certain degree of ‘‘metabolic
diversity’’ exists in PTCs. To investigate this possibility, we
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Medicine  Volume 94, Number 2, January 2015 MRPL44 as a Prognostic Marker in PTCestimated OCR and ECAR in HELA cells and thyroid cancer
cell lines using an XF analyzer. As shown in Figure 3A and B,
HELA cells showed a higher OCR and a lower ECAR compared
with most thyroid cancer cell lines, suggesting that they gen-
erate more ATP via OxPhos (oxidative phenotype) than via
glycolysis. BCPAP cells, a BRAFV600E positive PTC cell line,
showed a decreased OCR and the highest ECAR, which was in
agreement with the higher levels of glycolysis (glycolytic
phenotype) in this cell line. TPC1 cells, a PTC cell line
harboring a RET/PTC1 rearrangement, had relatively lower
levels of both OCR and ECAR, suggesting that this cell line
had the lowest metabolic rate (metabolically inactive). Inter-
estingly, HTH-7 cells, an ATC cell line, showed increased OCR
and ECAR, suggesting that this cell line generates its ATP via
both glycolysis and OxPhos (combined phenotype). XTC.UC1
cells, derived from a Hurthle cell cancer harboring mutations in
mitochondrial DNA (mtDNA), had a lower OCR and a higher
ECAR, as expected (glycolytic phenotype). In BN-PAGE,
HELA cells had the most abundant OxPhos complexes
(Figure 3C), whereas complex IV was barely detectable in
TPC1 cells (Figure 3C, lower panel). Consistent with the results
obtained using the XF analyzer, HTH-7 cells contained more
intact OxPhos complexes than TPC1 cells. Thus, the thyroid
average means were performed with the Mann–Whitney U test. D
ATP5A¼ ??, BN¼blue native, ECAR¼ extracellular acidification ra
ns¼ ??, OCR¼oxygen consumption rate, SDHB¼ ??, TPC1¼ ??,cancer cell lines displayed substantial metabolic diversity. The
classification of thyroid cancer cell lines according to metabolic
phenotype is shown in Figure 3D.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Heterogeneous Expression of OxPhos and MRPs
in PTC
Based on the results obtained using public repository data,
RT-PCR was performed using mRNA from primary PTC and
matched normal tissues to determine the expression status of
OxPhos and MRP genes. First, 12 patients whose preoperative
[18F]-fluorodeoxyglucose positron emission tomography (18F-
FDG PET) imaging was available were analyzed. Ten of the 12
cases showed a reduction in the expression of OxPhos and MRP
genes, including NDUFB3, NDUFA5, SDHD, CYC1, CYCS,
COX6A1, COX7B, ATP5G1, MRPL44, MRPL45, MRPS5,
MRPS11, MRPS28, and MRPS31. However, 3 cases showed
no change in the mRNA expression of OxPhos and MRP genes
compared with matched normal thyroid tissues such as a case no.
4 as shown in Figure 4A. Interestingly, 18F-FDG PET imaging
indicated that PTCs in all 12 cases had a nodular lesion in the
thyroid gland with increased uptake of 18F-FDG (Figure 4B),
suggesting high glycolytic activity. RT-PCR and 18F-FDG PET
imaging data indicated that the expression of OxPhos and MRP
mRNAswas heterogeneous, although glycolytic activitywas still
higher in PTCs than in normal thyroid tissue.
Correlation Between MRPL44 mRNA Expression
and Regional LNM
are mean SD. P<0.01, P<0.001. All P values are 2 sided.
HELA¼ ??, HTH-7¼ ??, BCPAP¼ ??, MTCO1¼ ??, NDUFB8¼ ??,
CRC2¼ ??, XTC.UC1¼ ??.To understand the clinical implications of metabolic diver-
sity in PTC, we analyzed potential correlations between expres-
sion of MRPL44 mRNA and clinicopathological parameters.
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FIGURE 4. Representative results of RT-PCR analysis of OxPhos and MRP mRNA expression, and 18F-FDG PET CT imaging. (A)
Representative results of RT-PCR analysis for NDUFB3, NDUFA5, SDHD, CYC1, CYCS, COX6A1, ATP5G1, MRPL44, MRPL45, MRPS5,
MRPS11, MRPS28, MRPS31, and glyceraldehyde-3-phosphate dehydrogenase. All experiments were repeated 3 times, and each
experiment was performed in triplicate. (B) Representative preoperative 18F-FDG PET CT image from the same patients mentioned
in (A). Arrows indicate thyroid nodular lesions that were confirmed as PTC by ultrasound-guided fine-needle aspiration cytology. 18F-FDG
PET¼ [18F]-fluorodeoxyglucose positron emission tomography, ATP5G1¼ATP synthase, Hþ transporting, mitochondrial Fo complex,
subunit C1 (subunit 9), COX6A1¼ cytochrome c oxidase subunit VIa polypeptide 1, COX7B¼ cytochrome c oxidase subunit VIIb,
CYC1¼ cytochrome c1, CYCS¼ cytochrome c, somatic, GAPDH¼ ??, MRP¼mitochondrial ribosomal protein, MRPL44¼MPR L44,
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Lee et al Medicine  Volume 94, Number 2, January 2015Based on the heterogeneous expression of MRPL44 and
NDUFA5, RT-PCR for MRPL44 was performed in 103 primary
PTC and matched normal thyroid tissue. Of these, 87 PTCs
(84.5%) showed a reduction in MRPL44 expression compared
with that in normal tissue, whereas 16 PTCs (15.5%) showed no
differences inMRPL44mRNA expression between tumoral and
normal tissues (data not shown). Interestingly, clinicopatholo-
gical analysis indicated that regional LNM, including lateral
neck node metastasis (N1b), was more frequent in PTCs that
exhibited no change in expression of MRPL44 mRNA
(P¼ 0.001, Table 1). Moreover, multivariate analysis clearly
indicated that no change in MRPL44 expression (indicated as
Group 2) increased the risk of lateral neck LNM after adjust-
ment for age, ETE, T-stage, and multifocality (odds ratio 9.267,
95% confidence interval 1.852–46.371, P¼ 0.007, Table 2).
MRPL45¼MPR L45, MRPS5¼MPR S5, MRPS11¼MRP S11, MRPS2
(ubiquinone) 1 a subcomplex, 5, NDUFB3¼NADH dehydrogena
ation, PTC¼papillary thyroid cancer, SDHD¼ succinate dehydrogDISCUSSION
Otto Warburg11 discovered that most cancer cells produce
cellular ATP using a high rate of glycolysis instead of OxPhos.
6 | www.md-journal.comThis observation can be clinically detected by performing
uptake imaging using FDG PET as shown in Figure 4B. The
Warburg effect might be related to mitochondrial damage in
cancer cells, or to adaptation to hypoxia within the tumor
microenvironment. Recently, the aberrant expression of glyco-
lytic enzymes, such as overexpression of mitochondrial bound
hexokinase and the M2 splice isoform of pyruvate kinase, was
reported as a possible cause of the Warburg effect.25,26 How-
ever, because mitochondria can produce much more cellular
ATP via OxPhos than via glycolysis, cancer cells still use
mitochondria to produce ATP for fatty acid synthesis and other
biosynthetic processes.20 In agreement with these recent obser-
vations concerning mitochondrial metabolism in cancer cells,
the GSEA data showed that OxPhos and MR gene sets are
coordinately downregulated in most PTCs, indicating that PTC
cells rely primarily on aerobic glycolysis for their energy needs.
However, 16.3% of PTCs in the GSE33630 data set and 15.5%
MRP S28, MRPS31¼MRP S31, NDUFA5¼NADH dehydrogenase
ubiquinone) 1 b subcomplex, 3, OxPhos¼oxidative phosphoryl-
se complex, subunit D.of PTCs in our cohort had the same amount of OxPhos andMRP
mRNA expression as normal thyroid tissues. In line with our
data, HPA also indicated that MRPL44 and NDUFA5
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinicopathological Characteristics of Patients With
PTC According to Expression of MRPL44 mRNA
MRPL44 mRNA Expression
Decreased
N¼ 87, n (%)
No Change
N¼ 16, n (%)
P
Value
Age, y 46.4 1.437 47.56 4.148 0.76
Tumor size, cm 2.209 0.098 2.319 0.183 0.65
T-stage
T1a 7 (8.0) 0 0.22y
T1b 15 (17.2) 4 (25.0)
T2 21 (24.1) 0
T3 44 (50.6) 12 (75.0)
T4 0 0
ETE
Negative 45 (51.7) 4 (25.0) 0.06y
Minimal 42 (48.3) 12 (75.0)
Extensive 0 0
Multifocality
Negative 70 (80.5) 12 (75.0) 0.72y
Unilateral 7 (8.0) 1 (6.3)
Bilateral 10 (11.5) 3 (18.8)
Regional lymph node
N0 40 (46.0) 5 (31.3) 0.001y
N1a 42 (48.3) 5 (31.3)
N1b 5 (5.7) 6 (37.5)
Distant metastasis
M0 87 (100) 15 (93.8) 0.16y
M1 0 1 (6.3)
TNM stage group
I 43 (49.4) 7 (43.8) 0.14y
II 10 (11.5) 1 (6.3)
III 6 (6.9) 0
IVA 25 (28.7) 5 (31.3)
IVB 3 (3.4) 3 (18.8)
IVC 0 0
ETE¼ extrathyroidal extension, mRNA¼ ??, MRPL44¼mitochon-
mitochondrial ribosomal protein L44, PTC¼ papillary thyroid cancer,
TNM¼ ??.
P values calculated by unpaired t test. Data are meanSD.
yP values calculated by x2 test or linear-by-linear association.
TABLE 2. Multivariate Analysis of the Association of LNM
(N1b) With Levels of Expression of MRPL44
LNM (N1b)
Odds
Ratio
95% Confidence
Interval
P
Value
MRPL44 group 2

10.619 2.582–40.038 0.001
MRPL44 group 2y 7.694 1.707–34.672 0.008
MRPL44 group 2z 9.267 1.852–46.371 0.007
ETE¼ extrathyroidal extension, LNM¼ lymph node metastasis,
MRPL44¼mitochondrial ribosomal protein L44.
Adjusted for age.
y In addition to adjustment, adjusted for T stage and extrathyroidal
extension.
z In addition to adjustmenty, adjusted for multifocality.
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Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.expression in a proportion of PTCs was similar to that in normal
thyroid tissues.
Proteins in the ETC originate from both nuclear DNA
(nDNA-encoded) and mtDNA (mtDNA-encoded).27 Because of
the different origins of proteins in the ETC, nDNA-encoded
ETC proteins synthesized in the cytosol become localized to
mitochondrial matrix via a translocase on the outer mitochon-
drial membrane and a translocase on the inner mitochondrial
membrane complexes.28 After translocation, nDNA-encoded
ETC proteins undergo an assembly process with mtDNA-
encoded ETC proteins to generate an intact OxPhos complex.29
During this process, transcription and translation processes
from mtDNA must be coordinated with cytosolic synthesis,
transport, and assembly of nDNA-encoded ETC proteins.30
For this reason, we found a strong positive correlation
between MRPs and ETC proteins in the results of our corre-
lation assay and gene network analyses (Figure 2), which
support our hypothesis that MRPL44 is a representative marker
of OxPhos.
HELA cells are used as a control cell line for the oxidative
phenotype because they have abundant mitochondria,31
whereas XTC.UC1 cells, originating from a Hurthle cell cancer,
are used as representatives of the glycolytic phenotype.32 As
expected, HELA cells had the highest OCR and the lowest
ECAR, whereas XTC.UC1 had the lowest OCR and the highest
ECAR. BCPAP cells, a BRAFV600E-positive PTC cell line, had
the glycolytic phenotype. However, HTH-7, which is a cell line
derived from an ATC, had a high OCR and a high ECAR,
indicating that although these cells rely on glycolysis, they also
use oxidative respiration (combined oxidative and glycolytic
phenotype). In support of the results of the functional analysis
using the XF analyzer, BN-PAGE also showed differences in
the amounts of OxPhos complexes between TPC1 (metaboli-
cally inactive in our study) and HTH-7 cells. Based on these
observations, we hypothesize that PTCs and thyroid cancer cell
lines can be separated into 2 groups with distinct metabolic
phenotypes, namely, a glycolytic phenotype group and a com-
bined (oxidative and glycolytic) phenotype group.
One of the most interesting findings in the present study is
that MRPL44 expression correlates with the presence of LNM.
The expression of MRPL44 can be used to identify the meta-
bolic phenotype in PTC; low expression indicates a glycolytic
phenotype, whereas high expression indicates a combined
phenotype. PTC with a combined metabolic phenotype, indi-
cated by a high level of MRPL44 expression and a high FDG
uptake, might have a growth advantage because of the high
amounts of ATP and abundant precursors of fatty acid synthesis
produced. However, because a functional assay using primary
PTC cells was not performed, we cannot definitively conclude
that the ETC functions properly in PTCs with abundant
MRPL44 expression. In addition, we did not investigate other
factors that affect metabolism, such as glutamine addiction,
somatic isocitrate dehydrogenase mutations, or glycine/serine
addiction in PTCs. These limitations will be explored in
future studies.
In conclusion, our data suggest that a proportion of
PTCs have a combined (oxidative and glycolytic)
metabolic phenotype, even though they still rely on glycolytic
activity for ATP generation. In addition, the metabolic pheno-
type can be determined by measuring the expression of
MRPL44, which we show to be a promising marker for the
MRPL44 as a Prognostic Marker in PTCprediction of lateral neck LNM. Future studies should focus on
the metabolic phenotyping of PTCs according to their level of
MRPL44 expression.
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